New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
10:36 EDTFOLDAmicus Theraputics presents additional data from Fabry monotherapy study
Amicus Therapeutics announced additional 6-month results from the first ongoing Phase 3 global registration study of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had genetic mutations identified as amenable to migalastat HCl in a cell-based assay. Study 011 consists of a 6-month, double-blind period when subjects received migalastat HCl 150 mg or placebo, a 6-month open label-follow up period when all patients received migalastat HCl, and an ongoing 12-month open-label extension. Initial top-line Stage 1 results previously reported in December, 2012 for the primary endpoint in Stage 1 did not meet statistical significance. The pre-specified primary and secondary analyses of the primary endpoint numerically favored migalastat HCl over placebo. In the primary responder analysis, 13/32 in the migalastat HCl group versus 9/32 in the placebo group demonstrated a 50% or greater reduction in kidney interstitial capillary GL-3 from baseline to month 6. Taken alone the secondary analysis of the absolute percent change in kidney interstitial capillary GL-3 from baseline to month 6 showed a median reduction of 41% in the migalastat HCl group versus a median reduction of 6% in the placebo group. Stage 1 results were highlighted in an oral platform presentation at the Lysosomal Disease Network WORLD Symposium.
News For FOLD From The Last 14 Days
Check below for free stories on FOLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
11:08 EDTFOLDHigh option volume stocks
Subscribe for More Information
11:06 EDTFOLDSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen discusses Amicus Therapeutics' Migalastat for Fabry's disease on an Analyst/Industry conference call to be held on July 23 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use